Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell disease: when to transfuse
source: Medscape
year: 2018
authors: Mary Hulihan
summary/abstract:Hello. I am Dr Mary Hulihan, a health scientist in the Division of Blood Disorders at the Centers for Disease Control and Prevention. Today I would like to talk about the indications for blood transfusion in patients with sickle cell disease, the complications associated with these transfusions, and how you can help reduce the risk for these complications in your patients.
For many patients with sickle cell disease, red blood cell transfusions are an important part of medical care, reducing both mortality and morbidity. Both the National Heart, Lung, and Blood Institute and the British Society for Haematology have published documents that underscore the many unique aspects of care that must be taken into account when transfusing this patient population.
Although transfusions can be highly beneficial in treating sickle cell disease–related issues, they are not without risks. There are three scenarios when blood transfusions should be considered for patients with sickle cell disease. First, certain acute illnesses, such as acute chest syndrome or severe exacerbation of anemia with splenic or hepatic sequestration, may call for a simple blood transfusion.
read more
+myBinderRelated Content
-
Sickle Cell Disease: After Years of Neglect Some Promise for SufferersIt’s Black History Month, when the nat...
-
Step toward gene therapy for sickle cell diseaseA team of researchers at the Stanford Un...
-
Possible Cure for Sickle Cell Found in ParisHematologists, sickle cell patients, and...
-
Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle...Objective: To evaluate the impact of an...
-
Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in Califor...Introduction: Osteonecrosis of the femor...
-
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe SCD and Transfusion-Dep...BOSTON & ZUG, Switzerland--(BUSINESS...
-
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for S...Emmaus Life Sciences, Inc. announced tod...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.